title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,GLUE,0.006905,Neutral,0.004193
Stocks That Hit 52-Week Lows On Monday,20220613T161842,https://www.benzinga.com/markets/options/22/06/27677156/52-weeks-high-and-low-article,GLUE,0.005366,Neutral,-0.012266
Stocks That Hit 52-Week Lows On Thursday,20220526T161527,https://www.benzinga.com/markets/options/22/05/27422270/52-weeks-high-and-low-article,GLUE,0.048646,Neutral,0.0087
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,GLUE,0.025139,Neutral,0.05757
